Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12549253 | 0.88 | LTA4H (0.59) | LTA4HBRD4CYSLTR2CYSLTR1MAPT | |
| SCHEMBL2886166 | 0.86 | LTA4H (0.57) | LTA4HBRD4CYSLTR2CYSLTR1MAPT | |
| SCHEMBL10726761 | 0.86 | LTA4H (0.57) | LTA4HBRD4CYSLTR2CYSLTR1SMN1; SMN2 | |
| SCHEMBL30257467 | 0.85 | LTA4H (0.56) | LTA4HBRD4CYSLTR2CYSLTR1MAPT | |
| SCHEMBL7045164 | 0.84 | BRD4 (0.54) | LTA4HBRD4CYSLTR2CYSLTR1MAPT | |
| SCHEMBL6937314 | 0.84 | MEN1 (0.62) | LTA4HBRD4CYSLTR2CYSLTR1MAPT | |
| SCHEMBL8981963 | 0.83 | BRD4 (0.56) | LTA4HBRD4CYSLTR2CYSLTR1MAPT | |
| SCHEMBL3466988 | 0.83 | CYSLTR2 (0.59) | LTA4HBRD4CYSLTR2CYSLTR1MAPT | |
| SCHEMBL23582833 | 0.82 | LTA4H (0.54) | LTA4HBRD4CYSLTR2CYSLTR1 | |
| SCHEMBL13141141 | 0.82 | LTA4H (0.54) | LTA4HBRD4CYSLTR2CYSLTR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649009-B2 | N-(trans-4-tert-butylcyclohexyl)-1-{4-[(1h-tetrazol-5-ylamino)carbonyl]benzyl }-3-(3,4,5-trifluoropbenyl)-1h-pyrazole-5-carboxamide; type 2 diabetes, hyperglycemia, diabetes or insulin resistance, Syndrome X, atherosclerosis | MERCK & CO., INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1765335-B1 | PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1765335-A4 | PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070203186-A1 | Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1765335-A2 | PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006017055-A2 | PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203186-A1 | Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use | AADAC, GOT2, GLS2 | LTA4H 1645/4885BRD4 446/4885CYSLTR2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.